Clinical and cellular roles for TDP1 and TOP1 in modulating colorectal cancer response to irinotecan

Molecular Cancer Therapeutics

Volumn 14, Issue 2, 2015, Pages 575-585

  Meisenberg, Cornelia ^a   Gilbert, Duncan C ^b   Chalmers, Anthony ^c   Haley, Vikki ^d   Gollins, Simon ^e   Ward, Simon E ^f   El Khamisy, Sherif F ^a,g,h  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d OPEN UNIVERSITY   (United Kingdom)

^e GLAN CLWYD HOSPITAL   (United Kingdom)

^f UNIVERSITY OF SUSSEX   (United Kingdom)

^g UNIVERSITY OF SHEFFIELD   (United Kingdom)

^h ZEWAIL CITY OF SCIENCE AND TECHNOLOGY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DNA TOPOISOMERASE; ENZYME; IRINOTECAN; MESSENGER RNA; SMALL INTERFERING RNA; TYROSYL DNA PHOSPHODIESTERASE 1; UNCLASSIFIED DRUG; CAMPTOTHECIN; PHOSPHODIESTERASE; TDP1 PROTEIN, HUMAN; TOP1 PROTEIN, HUMAN;

ARTICLE; CANCER SURVIVAL; CATALYSIS; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG RESPONSE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; BIOCATALYSIS; COLORECTAL TUMOR; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

BIOCATALYSIS; CAMPTOTHECIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHORIC DIESTER HYDROLASES; RNA, MESSENGER;

EID: 84923334778     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0762     Document Type: Article

References (46)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide; 2013. Lyon, France: IARC.
2. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007;370:143-52.
3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-14.
4. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-7.
5. Gollins SS, Myint AAS, Haylock BB, Wise MM, Saunders MM, Neupane RR, et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. J Clin Oncol 2011;29:1042-9.
6. Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer 2007;96:912-7.
7. Glynne-Jones R, Falk S, Maughan TS, Meadows HM, Sebag-Montefiore D. A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study. Br J Cancer 2007;96:551-8.
8. Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernandez-Losa J, et al. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clin Cancer Res 2010;16:2375-82.
9. Horisberger K, Erben P, Muessle B, Woernle C, Stroebel P, Kaehler G, et al. Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer. Anticancer Drugs 2009;20:519-24.
10. Znojek P, Willmore E, Curtin NJ. Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase. Br J Cancer 2014;111:1319-26.
11. Carroll J, Page TKW, Chiang S-C, Kalmar B, Bode D, Greensmith L, et al. Expression of a pathogenic mutation of SOD1 sensitizes aprataxin-deficient cells andmice to oxidative stress and triggers hallmarks of premature ageing. Hum Mol Genet 2014:ddu500.
12. Wang JC. Interaction between DNA and an Escherichia coli protein omega. J Mol Biol 1971;55:523-33.
13. Wang JC. DNA topoisomerases. Annu Rev Biochem 1996;65:635-92.
14. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ. A model for the mechanism of human topoisomerase I. Science 1998;279:1534-41.
15. Pommier Y, Pourquier P, Fan Y, Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998;1400:83-105.
16. Ashour ME, Atteya R, El-Khamisy SF. Topoisomerase mediated chromosomal break repair: emerging player in many games. Nat Rev Cancer. In press, 2015.
17. Strumberg D, Pilon AA, Smith M, Hickey R, Malkas L, Pommier Y. Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5′-phosphorylated DNA double-strand breaks by replication runoff. Mol Cell Biol 2000;20:3977-87.
18. Sordet O, Nakamura AJ, Redon CE, Pommier Y. DNA double-strand breaks and ATM activation by transcription-blocking DNA lesions. Cell Cycle 2010;9:274-8.
19. El-Khamisy SF, Saifi GM, Weinfeld M, Johansson F, Helleday T, Lupski JR, et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005;434:108-13.
20. Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J, Leppard JB, Champoux JJ. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. EMBO J 2005;24:2224-33.
21. Alagoz M, Chiang S-C, Sharma A, El-Khamisy SF. ATM deficiency results in accumulation of DNA-topoisomerase I covalent intermediates in neural cells. PLoS ONE 2013;8:e58239.
22. Miao ZH, Agama K, Sordet O, Povirk L, Kohn KW, Pommier Y. Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst) 2006;5:1489-94.
23. Lebedeva NA, Rechkunova NI, El-Khamisy SF, Lavrik OI. Tyrosyl-DNA phosphodiesterase 1 initiates repair of apurinic/apyrimidinic sites. Biochimie 2012;94:1749-53.
24. Alagoz M, Wells OS, El-Khamisy SF. TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy. Nucleic Acids Res 2014;42:3089-103.
25. Hudson JJR, Chiang S-C, Wells OS, Rookyard C, El-Khamisy SF. SUMO modification of the neuroprotective protein TDP1 facilitates chromosomal single-strand break repair. Nat Commun 2012;3:733-13.
26. Katyal S, El-Khamisy SF, Russell HR, Li Y, Ju L, Caldecott KW, et al. TDP1 facilitates chromosomal single-strand break repair in neurons and is neuroprotective in vivo. EMBO J. 2007;26:4720-31.
27. Barthelmes HU, Habermeyer M, Christensen MO, Mielke C, Interthal H, Pouliot JJ, et al. TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II. J Biol Chem 2004;279:55618-25.
28. Chiang S-C, Carroll J, El-Khamisy SF. TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage. Cell Cycle 2010;9:588-95.
29. El-Khamisy SF, Hartsuiker E, Caldecott KW. TDP1 facilitates repair of ionizing radiation-induced DNA single-strand breaks. DNA Repair (Amst) 2007;6:1485-95.
30. Zhou T, Lee JW, Tatavarthi H, Lupski JR, Valerie K, Povirk LF. Deficiency in 3′-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1). Nucleic Acids Res 2005;33:289-97.
31. Zhou T, Akopiants K, Mohapatra S, Lin PS, Valerie K, Ramsden DA, et al. Tyrosyl-DNA phosphodiesterase and the repair of 3′-phosphoglycolate-terminated DNA double-strand breaks. DNA Repair (Amst) 2009;8:901-11.
32. Alagoz M, Gilbert DC, El-Khamisy S, Chalmers AJ. DNA repair and resistance to topoisomerase I inhibitors: mechanisms, biomarkers and therapeutic targets. Curr Med Chem 2012;19:3874-85.
33. Walker S, Meisenberg C, Bibby RA, Askwith T, Williams G, Rininsland FH, et al. Development of an oligonucleotide-based fluorescence assay for the identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors. Anal Biochem 2014;454:17-22.
34. Marchand C, Lea WA, Jadhav A, Dexheimer TS, Austin CP, Inglese J, et al. Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay. Mol Cancer Ther 2009;8:240-8.
35. Weidlich IE, Dexheimer T, Marchand C, Antony S, Pommier Y, Nicklaus MC. Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) developed by virtual screening using ligand-based pharmacophores. Bioorg Med Chem 2010;18:182-9.
36. Breslin C, Clements PM, El-Khamisy SF, Petermann E, Iles N, Caldecott KW. Measurement of chromosomal DNA single-strand breaks and replication fork progression rates. Meth Enzymol 2006;409:410-25.
37. El-Khamisy SF. To live or to die: a matter of processing damaged DNA termini in neurons. EMBO Mol Med 2011;3:78-88.
38. Koopman M, Venderbosch S, van Tinteren H, Ligtenberg MJ, Nagtegaal I, Van Krieken JH, et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. Eur J Cancer 2009;45:1999-2006.
39. Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets. Br J Cancer 2011;106:18-24.
40. El-Khamisy SF, Katyal S, Patel P, Ju L, McKinnon PJ, Caldecott KW. Synergistic decrease of DNA single-strand break repair rates in mouse neural cells lacking both Tdp1 and aprataxin. DNA Repair (Amst) 2009;8:760-6.
41. Meisenberg C, Ward SE, Schmid P, El-Khamisy SF. TDP1/TOP1 ratio as a promising indicator for the response of small cell lung cancer to topotecan. J Cancer Sci Ther 2014;6:258-67.
42. Zeng Z, Sharma A, Ju L, Murai J, Umans L, Vermeire L, et al. TDP2 promotes repair of topoisomerase I-mediated DNA damage in the absence of TDP1. Nucleic Acids Res 2012;40:8371-80.
43. Hamilton NK, Maizels N. MRE11 function in response to topoisomerase poisons is independent of its function in double-strand break repair in saccharomyces cerevisiae. PLoS ONE 2010;5:e15387.
44. Zhang YW, Regairaz M, Seiler JA, Agama KK, Doroshow JH, Pommier Y. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. Nucleic Acids Res 2011;39:3607-20.
45. Regairaz M, Zhang Y-W, Fu H, Agama KK, Tata N, Agrawal S, et al. Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J Cell Biol 2011;195:739-49.
46. Hartsuiker E, Mizuno K, Molnar M, Kohli J, Ohta K, Carr AM. Ctp1CtIP and Rad32Mre11 nuclease activity are required for Rec12Spo11 removal, but Rec12Spo11 removal is dispensable for other MRN-dependent meiotic functions. Mol Cell Biol 2009;29:1671-81.